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Phospho-MurNAc-pentapeptide translocase (MraY) catalyzes
the synthesis of Lipid I, a bacterial peptidoglycan precursor. As
such, MraY is essential for bacterial survival and therefore is an
ideal target for developing novel antibiotics. However, the under-
standing of its catalytic mechanism, despite the recently deter-
mined crystal structure, remains limited. In the present study, the
kinetic properties ofBacillus subtilisMraY (BsMraY)were investi-
gated by fluorescence enhancement using dansylated UDP-Mur-
NAc-pentapeptide and heptaprenyl phosphate (C35-P, short-
chain homolog of undecaprenyl phosphate, the endogenous
substrateofMraY)as secondsubstrate.Varying theconcentrations
of both of these substrates and fitting the kinetics data to two-sub-
strate models showed that the concomitant binding of both UDP-
MurNAc-pentapeptide-DNS andC35-P to the enzyme is required
before the release of the twoproducts, Lipid I andUMP.Webuilt a
model of BsMraY and performed docking studies with the sub-
strate C35-P to further deepen our understanding of how MraY
accommodates this lipid substrate. Based on thesemodeling stud-
ies, a novel catalytic role was put forward for a fully conserved his-
tidineresidue inMraY(His-289 inBsMraY),whichhasbeenexper-
imentally confirmed to be essential for MraY activity. Using the
currentmodel of BsMraY,we propose that a small conformational
change is necessary to relocate the His-289 residue, such that the
translocasereactioncanproceedviaanucleophilicattackof thephos-
phatemoiety ofC35-PonboundUDP-MurNAc-pentapeptide.
Among the enzymes involved in bacterial peptidoglycan syn-
thesis, phospho-N-acetylmuramyl-pentapeptide translocase
(MraY4; EC 2.7.8.13) has been studied extensively (1, 2). This
enzyme performs the initial membrane step in this process,
forming undecaprenyl-N-acetylmuramyl-pentapeptide (Lipid
I) from UDP-N-acetylmuramyl-pentapeptide (UDP-MurNAc-
pentapeptide) andundecaprenyl phosphate, in bothGram-pos-
itive and Gram-negative bacteria. Given the role of MraY in
bacterial cell wall synthesis (3, 4) and cell growth (5), this
enzyme is an interesting target for antibacterial drugs. Recently,
the crystal structure of MraY from the Gram-negative species
Aquifex aeolicus (Protein Data Bank entry 4J72) was deter-
mined (6). The enzyme was extracted from its membrane envi-
ronment with detergent and crystallized as a symmetrical
homodimer. Eachprotomer consists of 10 transmembraneheli-
ces, with both the N and C termini locating on the periplasmic
side (outside) of the cytoplasmicmembrane (1). Before the pub-
lication of this high resolution (3.3 Å) structure, other studies
attempted to unravel the catalytic mechanism of action of
MraY by site-directed mutagenesis and kinetics studies, using
either membrane-embeddedMraY or detergent-extracted and
purified preparations (1, 7, 8). These studies proposed that
catalysis proceedsmost likely via a one-step process, although a
two-step process has also been suggested (1). In the single-step
process, a ternary complex of MraY, UDP-MurNAc-pentapep-
tide, and undecaprenyl phosphate (C55-P) yields Lipid I with
concomitant release of UMP. In the two-step process, UMP is
released, yielding a covalently bound phospho-MurNAc-pen-
tapeptide intermediate that is subsequently attacked by C55-P
to produce Lipid I. However, no direct experimental evidence
was provided for either proposal. The kinetics values of MraY
for its nucleotide and lipid substrates that have been reported in
literature so far are not consistent with each other. Bouhss et al.
(7) obtained theKm value ofMraY by varying the concentration
of one substrate while keeping the other at a fixed value. The
authors reported apparent Km values for UDP-MurNAc-pen-
tapeptide and C55-P of 1.0  0.3 and 0.16  0.08 mM, respec-
tively. This result was later challenged by another study (9)
reporting an apparent Km value for UDP-MurNAc-pentapep-
tide at 36.2 3.6 M. The major difference between these two
studies is the concentration of C55-P used in the reaction,
namely 1.1 mM (7) and 50 M (9). This indicates that the
concentration of both substrates should be varied to allow
determination of the true Km value. In the present study, we
performed more extensive kinetics studies on the detergent-
solubilized MraY. Pure heptaprenyl phosphate (C35-P) was
used as the preferred lipid substrate throughout our study.
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OtherMraY studies (10, 11) have also reported the use of C35-P
instead of the natural lipid substrate C55-P. Polyprenyl phos-
phates with shorter chain lengths are also accepted as sub-
strates byMraY (12), but to the best of our knowledge, the exact
effect of the prenyl chain length on the activity ofMraY has not
yet been studied in detail. Together with kinetic studies, we
built a model forMraY from Bacillus subtilis, carried out dock-
ing experiments with C35-P, and analyzed the conserved resi-
dues in both Gram-positive and Gram-negative MraY species.
The shortened chain length of C35-P compared with C55-P
makes the docking results more reliable because of the reduced
number of possible conformations of the prenyl chain. Many
algorithms/programs are available for predicting protein-sub-
strate binding. The majority of these approaches, however,
focus on soluble proteins in an aqueous environment because
more experimental data are available. For our docking studies,
HADDOCK (high ambiguity driven protein-protein docking)
(13), an approach developed for protein complex docking based
on biochemical and/or biophysical interaction data, was used.
Unlike other docking methods, HADDOCK uses ambiguous
interaction restraints to drive the docking. The docked struc-
tures are given a HADDOCK score, after calculations, accord-
ing to their intermolecular energy, namely a weighted sum of
desolvation, van derWaals, electrostatic, and ambiguous inter-
action restraint energy terms. In our case, the default desolva-
tion energy term for aqueous protein docking was neglected,
and a novel “z-restraint” was introduced to keep our model in
the right orientation in the simulated membranes. Together,
our findings provided a novel concept for the development of
MraY inhibitors and imply that blocking the binding of the lipid
substrate to the enzyme, by targeting His-298, may be a viable
approach. This is of great interest, given that the inhibitor
development for MraY has not been very successful so far.
Results
N-Dodecyl--D-maltopyranoside (DDM)-BsMraY Kinetics—
To understand the catalytic mechanism of MraY and how its
activity is controlled, it is important to consider the binding of
both substrates to the enzyme and thus vary both of their con-
centrations during the kinetics studies. This has been previ-
ously neglected in kinetic analysis of MraY activity (7, 9). The
kinetics of BsMraY extracted from the Escherichia coli mem-
brane with 1% DDM detergent were investigated by varying
both substrates, C35-P andUDP-MurNAc-pentapeptide-DNS,
yielding a dansylated product DNS-Lipid I and UMP. Produc-
tion of DNS-Lipid I was monitored using fluorescence
enhancement measurements (14). Immediately after the addi-
tion of enzyme, the fluorescence signal increased linearly for
several minutes. The reaction was followed until a plateau was
reached. This plateau value was then used to convert the fluo-
rescence signal into concentration of DNS-Lipid I. Slopes
obtained from the linear part of the reaction traces could then
be expressed in M/min of Lipid I formed. These values were
finally divided by the concentration of MraY to obtain reaction
rates k (min1). Reaction rates were collected using a range of
concentrations of one substrate while maintaining the concen-
tration of the other constant. The experiments were repeated at
least three times for six concentrations of both UDP-MurNAc-
pentapeptide-DNS and C35-P. All experimental data were fit-
ted to the equations for either a two-substrate model (Fig. 1A)
or ping-pongmechanism (Fig. 1B). Better fit was obtained for a
random bi-bi model (SSE (sum of squared errors of predic-
tion) 8330.1, RMSE (root mean square error) 9.2) than for
a ping-pongmodel (SSE 8655.3, RMSE 9.4), indicating that
a ternary complex is formed between the enzyme, UDP-Mur-
NAc-pentapeptide-DNS, and C35-P.
When the data as shown in Fig. 2 were fitted separately at
constant C35-P concentrations, an apparent maximum turn-
over kcat(app) and KmappUMpp were obtained at the various levels of
C35-P used. Replotting these apparent parameters as a function
of C35-P (Fig. 3) yielded the maximum turnover (kcat) and the
true Km values for C35-P and UDP-MurNAc-pentapeptide-
DNS, and KsC35-P. The dependent variable KsUMpp was calcu-
lated from the other three constants. In Table 1, the results are
summarized.
FIGURE 1. Kinetic models used to derive the rate equations for the MraY-catalyzed reaction. A, random bi-bi kinetic mechanism, in which MraY binds in
a random order to its two substrates; the two products will only be released after a ternary complex is formed betweenMraY and its substrates. In this model,
the substrates bind to the same enzyme species. B, ping-pongmechanism, in which one of the substrates binds first, and a first product is formed. The second
substrate therefore binds to a modified enzyme species, and a second product is then released.
FIGURE 2. Turnover of DNS-Lipid I formation (k) as a function of UDP-
MurNAc-pentapeptide-DNS concentration and at several concentra-
tions of C35-P (20 M (E), 35 M (Œ), 50 M (‚), 100 M (ƒ), 200 M (),
and 400M (F)). Error bars, S.E.
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These data show that Km for either substrate increases by 1
order of magnitude when a ternary complex is formed com-
pared with binding of either substrate in binary complex
formation.
Exchange betweenUDP-MurNAc-Pentapeptide andUridine-
[15N2]5-Monophosphate ([15N2]UMP)—The choice of the ran-
dombi-bimechanism forMraY catalysis, based on better fitting
data, could be supported by a mass spectrometry-based exper-
iment devised to detect exchange between [15N2]UMP and
UDP-MurNAc-pentapeptide either in the absence or presence
of C35-P. In such an experiment, the exchange reaction will
result in the formation of unlabeled 14N2-UMP from unlabeled
UDP-MurNAc-pentapeptide, resulting in a mass difference
in UMP of 2 Da that can be detected by LC-MS analysis. At
the same time, the reverse reaction will catalyze the transfer
of [15N2]uridine from uridine-[15N2]5-monophosphate to
UDP-MurNAc-pentapeptide, resulting in the formation of
[15N2]UDP-MurNAc-pentapeptide. To investigate under
which conditions exchange occurred, UDP-MurNAc-penta-
peptide (100 M) and [15N2]UMP (1 mM) were incubated with
DDM-BsMraY in the absence or presence of C35-P for 16 h.
Given that the major difference between the two models is the
requirement of polyprenyl phosphate for the hydrolysis of
UDP-MurNAc-pentapeptide and formation of Lipid I, the
reaction was performed using pure enzyme devoid of C55-P
instead of enzyme-containing membranes where C55-P was
still present. It should also be noted that incubations were car-
ried out with a 10-fold higher concentration of [15N2]UMP rel-
ative to unlabeled UDP-MurNAc-pentapeptide to clearly
observe the reverse reaction and the formation of 15N-labeled
UDP-MurNAc-pentapeptide. After removal of the detergent,
the resulting reaction mixture was analyzed by LC-MS. It was
found that in the absence of C35-P, no 14N2-UMP was pro-
duced, and no 15N2 was transferred from UMP to UDP-Mur-
NAc-pentapeptide. However, in the presence of 100MC35-P,
both 14N2-UMP and [15N2]UDP-MurNAc-pentapeptide were
found in the mixture, as shown in Fig. 4. This clearly demon-
strates that an exchange between UMP and UDP-MurNAc-
pentapeptide happens only when C35-P is available.
Structural Model of BsMraY—Given the results from the
aforementioned kinetics and exploration of the exchange reac-
tion, a structure would be very helpful in giving more insight
into the catalytic mechanism of BsMraY. Because there is no
crystal structure of BsMraY available, we built a homology
model based on the structure ofMraY fromA. aeolicus. Protein
sequence databases contain over 5000 MraY sequences (PFam
PF10555 and IPR018480). Following a BLAST search, aligning
the sequences of MraY of both Gram-positive and Gram-neg-
ative species reveals that more than 50 amino acids are fully
retained in these two families. Based on sequence analysis,
AaMraY and BsMraY are good representatives of all Gram-
negative and Gram-positive MraY families, respectively. Given
the lack of structure for BsMraY (Uniprot ID: Q03521), we pro-
duced amodel based on the available AaMraY structure. Only a
small region of the model is considered “poorly modeled,” cor-
responding to the disordered loop region of BsMraY (residues
30–53) that does not exist in A. aeolicus MraY and that does
notmake part of our predicted interface with C35-P (see “Iden-
tity and Location of Conserved Residues”). The best-ranked
model, according to the DOPE statistical potential imple-
mented in MODELLER, is shown in Fig. 5 together with the
structure of AaMraY. The models are viewed from the plane of
the membrane, as calculated by the PPM2.0 server (15). Two
short -helices are present in Gram-negative MraY species
FIGURE 3. Replots of kcat(app) (f; left) and Kmapp
UMpp (F; right) as a function of C35-P concentration. The apparent turnover rate increases as C35-P concen-
tration increases, and the binding affinity of UDP-MurNAc-pentapeptide to MraY decreases. Error bars, S.E.
TABLE 1
Kinetic parameters obtained for BsMraY
KmUMpp KmC35-P KsUMpp KsC35-P kcat
M M M M min1
167 18 121 23 18 31 13 11 434 35
FIGURE4.LC-MSanalysisof theproductsofa reactionmixturecontaining
MraY, 14N2-UDP-MurNAc-pentapeptide, and [
15N2]UMP in the absence
and presence of C35-P. Two groups of columns are shown for these two
different conditions of the assay. In the left group, where C35-P is absent, only
14N2-UDP-MurNAc-pentapeptide and [
15N2]UDP-MurNAc-pentapeptide
were detected. In the right group, where 100 M C35-P was included,
[15N2]UDP-MurNAc-pentapeptide and
14N2-UDP were detected as a result of
an exchange reaction. Error bars, S.E.
Catalytic Mechanism ofMraY
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only. One of these is present at the N terminus of MraY from
A. aeolicus and is proposed to align with the surface of the
membrane (6), whereas the other is found between TM6 and
TM7 and located in the periplasm.
Two transmembrane helices, TM5 and TM9, in purple and
dark red in Fig. 5, respectively, are relevant for this study in
particular. There are no significant differences between the
predicted lengths and orientations of these helices in the
BsMraY model when compared with the structure of AaMraY;
TM9 is strongly twisted, whereas TM5 is slanted relative to the
other transmembrane helices, giving rise to a nearly perpendic-
ular orientation of TM5 with respect to the C-terminal part of
TM9. The transmembrane helix TM5 points toward the highly
conserved His-324 in AaMraY or His-289 in BsMraY, shown in
blue sticks in Fig. 5. This histidine residue was shown to be
catalytically important, but no clear role had been attributed to
this residue (7, 16). We also observed that the mutant H289R is
virtually inactive in both the TLC-based Lipid II synthesis assay
and the Lipid I synthesis-based fluorescence enhancement
assay (data not shown).
Identity and Location of Conserved Residues—All conserved
amino acids, grouped with respect to their properties, are listed
in Table 2 along with their location in the protein structure of
BsMraY. With the exception of Glu-251 and Lys/Arg-249, all
residues are located at the cytosolic side of MraY quite close to
the Mg2 ion (average distance 11 5 Å). For the highly con-
served His-45, no reliable structural data are available (the cor-
responding His-67 coordinates are missing in Protein Data
Bank entry 4J72). Residues that are not retained in MraY spe-
cies from plants aremarked with an asterisk.When the analysis
is expanded to include the functionally related proteins TarO,
TagO, RgpG,WbpL,WbcO, andWecA, one finds some 20 fully
conserved amino acids. These residues are shown in boldface
type in Table 2. The fully conserved His-289 is at a distance of
8.4 Å from the Mg2 ion. Apart from being close to Mg2,
several conserved residues are close together in space, most
likely for structural reasons (e.g. Phe-228 in the loop between
TM7 andTM8withGly-178 andAsp-174 in TM5). It should be
noted that the conserved Lys-102 residue is located very close
to Mg2 but is replaced by Ile in Staphylococcus aureusMraY.
Docking of C35-P to the Model of BsMraY—Because no crys-
tal structure of BsMraY with its lipid substrate is available, we
attempted to predict the binding mode of BsMraY to C35-P
through docking studies. Inspection of the BsMraYmodels sug-
FIGURE 5. Structural models of BsMraY (left) and AaMraY (right). The structures are viewed from the plane of the membrane: cytoplasmic (inside) and
periplasmic (outside) regions at the top and bottom, respectively. The membrane is represented by the yellow lines and placed as calculated by the PPM2.0
server. Both structures are colored from green (N terminus) to yellow (C terminus), with the catalytic Mg2 represented as a gold sphere and His-289 (B. subtilis)
and His-324 (A. aeolicus) in blue sticks. The two transmembrane helices central to the modeling studies, TM5 and TM9, are colored purple and dark red,
respectively, inboth structures. Theback viewhighlights thedifferencesbetween the two structures, namely two-helices (inmagentaon the cytoplasmic side
and in green at the N terminus) that are present only in MraY from Gram-negative species.
Catalytic Mechanism ofMraY
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gested that flexibility might play a role in substrate binding, in
particular the orientation of TM9. Given the limited ability of
HADDOCK to sample large conformational changes, we used
CONCOORD to generate additional conformers of BsMraY.
These conformers were then used to seed new docking calcu-
lations using the same parameters and restraints as before.
Indeed, after correcting for the disordered and poorly modeled
loops in the BsMraY model, CONCOORD hints that the high-
est flexibility inMraY is found at the C-terminal tip of TM9 and
part of the connecting residues between TM9 and TM10 (resi-
dues271–285). This part ofMraY is highly positively charged
due to the presence of four or five Lys and/or Arg residues,
depending on different MraY species, of which Lys/Arg-276,
Arg-281, and Lys/Arg-284 are fully conserved (Table 2). The
N-terminal part of TM9 is much less flexible, probably helped
by the proximity of the conserved Lys-249 and Glu-251 resi-
dues. High flexibility, but to a lesser extent, was found in the
loop connecting TM3 and TM4. In this loop, at the C-terminal
end of TM3 and the N-terminal end of TM4, again many Lys
and/or Arg residues are located, of which Lys/Arg-114 and Lys-
116 are highly conserved (Table 2).
The docking studies yielded nine possible binding modes for
C35-P (see Table 3). All models are consistent in that MraY
seems to fully accommodate only seven isoprene units of the
polyprenyl phosphates. This predicts that the lipid tail of natu-
ral polyprenyl phosphates containing 11 isoprene units, as in
C55-P, will not bind completely to MraY. The clusters differ
mainly in the conformation of C35-P and consequent interac-
tions that it makes with MraY residues and its coordinated
magnesium ion. Clusters 6, 4, 7, and 9 have very shallow inter-
faces and are unlikely to represent realistic binding modes, as
indicated by their low HADDOCK score. Clusters 5 and 8,
despite being the top scoring clusters, do not show any signifi-
cant interactions between the phosphate moiety and anyMraY
residues and have therefore been discarded from subsequent
analyses. Clusters 2 (blue in Fig. 6) and 1 favor interactions with
the magnesium coordination center and the ion itself, whereas
cluster 3 (green in Fig. 6) shows a bindingmodewhere the phos-
phate of C35-P is in close proximity with His-289 (dark pink in
Fig. 6), whichmay indicate that this residue is important for the
interaction with the phosphate and would explain the loss of
activity upon modification of this residue (see more details
under “Discussion”). In cluster 3, the entire C35-P molecule is
in an extended conformation alongTM5, also in proximitywith
highly conserved residues of TM9 (Glu-264, Ser-267, Val-268,
and Gln-271). In the remaining clusters, C35-P shows a kink
near the phosphate group. The several clusters also select dif-
ferent conformers of MraY, in particular of TM9, indicating
that there might be a conformational mechanism involving
transmembrane helix reorientation to better accommodate the
ligand.
Discussion
Kinetics of Detergent-solubilized BsMraY—BsMraY was cho-
sen as a representative phospho-MurNAc-pentapeptide trans-
locase from Gram-positive species due to its robust properties,
although structural information was lacking. In contrast to
E. coliMraY, BsMraY shows high activity after resolubilization
in detergent systems (9). Similar to otherMraY studies (10, 11),
pure C35-P was used as the lipid substrate in our kinetics stud-
ies to be consistent with our docking studies. Interestingly, it
was previously found that at least 35 carbon units were required
for the polyprenyl phosphate to be a substrate of WecA, an
TABLE 2
Conserved residues in MraY family
Residue numbering is given for BsMraY. Lys-102 is replaced by Ile in S. aureus
MraY. The location of each residue is listed: TM, transmembrane helix. Loops
between transmembrane helices are indicated by the numbers of the two flanking
helices. The shortest distances to Mg2 ion are shown for all residues. For residue
His-45 () structural data are lacking. Shown in boldface are residues that are also
retained in related proteins. Shown in italic type residues within 10Å of the Mg2
ion. *, residues that are not retained in MraY from plant species. Hydrophobic
residues are shaded.
TABLE 3
Statistics of scoring and relevant distances for each cluster after explicit solvent refinement
All values are averages and S.D. calculated from the best scoring four models of each cluster. Distances to the C35-P are reported from the phosphorous atom. z-score,
standard score; vdW, van der Waals; Elec, electrostatic; AIRs, ambiguous interaction restraints; BSA, buried surface area.
Cluster HADDOCK score z-Score Size
Energy terms
BSA
Distances to C35-P
vdW Elec AIRs Mg His-289 Asp-98
kcal/mol Å2 Å
5 51 3 1.2 18 48 10 114 18 2.6 1 1253 59 7.6 2.6 15.1 1.5 5.9 1.8
2 47 6 1.1 98 39 5 141 23 18 15 1224 69 3.1 0.2 10.9 2.3 5.2 1.2
8 39 12 0.8 7 50 4 87 20 4 2 1264 35 9.3 0.9 14.3 2.8 5.8 2.1
1 35 1 0.6 169 34 3 104 19 18 17 1037 25 5.5 1.9 10.3 2.4 6.3 1.3
3 28 4 0.3 47 35 2 45 10 31 31 1118 39 10.1 1.4 4.2 1.6 14.0 2.5
6 10 7 0.5 13 26 3 60 32 8 10 906 91 9.1 0.9 13.0 2.8 11.4 2.0
4 9 7 0.5 24 21 1 44 55 34 17 848 39 7.3 2.3 7.2 1.3 10.5 1.9
7 14 7 1.4 9 19 3 78 26 72 23 665 128 12.8 2.2 16.3 1.7 12.4 3.1
9 18 11 1.6 4 20 6 62 28 95 16 703 135 13.0 1.9 16.9 2.3 10.8 1.6
Catalytic Mechanism ofMraY
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enzyme that is functionally similar to MraY (17). Our kinetics
studies using fluorescence enhancement show that the appar-
ent affinity for UDP-MurNAc-pentapeptide depends on the
concentration of C35-P and vice versa. This means that the
concomitant binding of UDP-MurNAc-pentapeptide and
C35-P forming a ternary complex with MraY occurs before
liberation of the products Lipid I andUMP. Furthermore, it was
shown that binding affinities for UDP-MurNAc-pentapeptide
and C35-P are relatively low (i.e. Km values are in the high
micromolar range for either substrate when a ternary complex
is formed). In contrast, the binding affinities for single substrate
binding are much higher. These affinities could not be deter-
mined accurately but are about 1 order of magnitude higher
than the corresponding affinities in ternary complex formation.
In summary, the kinetics study supports models in which ter-
nary complexes between MraY and the two substrates are
formed but clustering of the two substrates makes it harder for
either substrate to bind in the presence of the other substrate
than to bind to MraY alone. This indicates that in the ternary
complex formed during catalysis, the two substrates bind
closely together to allow the reaction to occur without the need
for a covalently bound substrate-MraY intermediate.
In previous kinetic studies on BsMraY using radioactively
labeled UDP-MurNAc-pentapeptide (e.g. Bouhss et al. (7, 8)),
only affinities for either substratewere obtained in the presence
of fixed (saturating) concentrations of the other. Compared
with our studies, the turnover ofMraY found (320 25min1)
is close to our result (434 35 min1). The Km found by us for
UDP-MurNAc-pentapeptide (0.167 0.018 mM) is lower than
the value reported (0.94 0.15mM). Interestingly, although the
polyprenyl substrate used (C55-P) differed from ours (C35-P),
the Km values are quite close: 0.16 0.04 mM for C55-P (7) and
0.12  0.02 mM for C35-P (see also “Docking of Polyprenyl
Phosphate”). In other kinetic studies, a very low Km value for
UDP-MurNAc-pentapeptide (19M)was reported (10, 18).We
only observed such a high affinity (KsUMpp 18 M) for UDP-
MurNAc-pentapeptide binding to MraY when the concentra-
tion of C35-P was extrapolated to zero (see Fig. 3 or Table 1).
We propose, therefore, that a high apparent affinity for UDP-
MurNAc-pentapeptidewill be observedwhen the translocase is
not saturated with the polyprenyl phosphate substrate. This
can be verified by quantifying the amount of Lipid I formed
under the conditions used.
Docking of Polyprenyl Phosphate—Chung et al. (6) proposed
a mode of binding of C55-P where the phosphate moiety of
C55-P is located close to Asp-117 (Asp-98 in BsMraY) of
AaMraY. In addition, they predicted the polyprenyl chain to
bend sharply, in order to allow such a location for the phos-
phate. Although the authors confirmed that His-324 (His-289
in BsMraY) is involved in catalysis, no catalytic role was attrib-
uted to this highly conserved histidine residue. In our docking
studies, the only (initial) assumptionsmade were the likelihood
(based on an initial unbiased docking run) of the polyprenyl tail
of C35-P to bind along TM5 in MraY and the directionality of
the C35-P substrate. In all four best scoring binding modes,
C35-Pwas bound in a kinked fashion in the isoprene chain near
the phosphate moiety. Furthermore, in these modes, the phos-
phate is found close to Asp-98 with its OH hydrogen pointing
toward the carboxylate oxygens of Asp-98. Because we were
unable to dock the other substrate, UDP-MurNAc-pentapep-
tide, as well, it remains to be established whether the binding
modes for polyprenyl phosphates near Asp-98 would be
affected by the other substrate. Close inspection of the models
predicts that in principle, there is room for the diphosphate of
UDP-MurNAc-pentapeptide to bind in the neighborhood of
the catalytic Mg2 ion, even when C35-P binds closely to
Asp-98 and the Mg2 ion. In the fifth best scoring cluster,
C35-P is bound in an extended fashion, where the phosphate
moiety is located very close to the aromatic ring of His-289.
This suggests a direct involvement of His-289 in the transfer of
the phosphate moiety of polyprenyl phosphate as described
below. It should be noted that docking of C55-P was compli-
cated because of the parameterization and flexibility of this
molecule. Our activity test indicated that the longer chain of
C55-P does not contribute to or improve binding toMraY (data
not shown).
Catalytic Role of His-289—Our docking studies hint at two
possible scenarios in which His-289 is involved in the catalytic
FIGURE 6.Different bindingmodes of C35-P to BsMraY suggested by themodeling. Left, side view of the bindingmodes of clusters 2 (blue) and 3 (green).
Right, top view of the same clusters, highlighting important residues (sticks, light pink) near the phospho-binding site. Interhelical loops are omitted for clarity,
except for those containingHis-289 (sticks, dark pink). The red/orange spheres represent the oxygen and phosphorous atoms of the phosphate group of C35-P,
whereas the gold spheres represent magnesium ions.
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mechanism ofMraY (i.e. by binding to the phosphate moiety of
theC35-P forming a phosphoramidate bondbetweenone of the
nitrogen atoms and the phosphorous atom of the polyprenyl
phosphate substrate). Alternatively, His-289 may act as a base,
thereby activating the phosphate for reaction with UDP-Mur-
NAc-pentapeptide. In either scenario, a small conformational
change (involving TM9) will be needed to bring the phosphate
moiety a fewÅ closer to the catalyticMg2 ion, thereby kinking
the isoprene chain as we observed for clusters 5, 2, 8, and 6 (Fig.
6, right). In the event that a covalent bond is formed, dephos-
phorylation of His-289 can be catalyzed by nearby acidic
groups, such as Asp-174, after the conformational change.
Using our kinetic analysis, we tried to verify the finding of Al-
Dabbagh et al. (8) that themutationH289R apparently does not
affect the affinities for UDP-MurNAc-pentapeptide and C55-P
while lowering catalytic turnover by 5 orders of magnitude. It
turned out, however, that no reliable affinities could be
obtained, due to the very high enzyme concentration needed
(400 M) to observe turnover (data not shown). Under these
conditions, the steady state assumption used in Michaelis-
Menten kinetics no longer applies, and hence the calculation of
Km is invalid. Such a catalytic role of His-289 as depicted above
is comparable with the involvement of a histidine residue in the
activity of undecaprenyl pyrophosphate phosphatase UppP
from E. coli (19). The catalytic histidine in UppP was proposed
to act either as a base or by forming a phosphoramidate bond
with undecaprenyl pyrophosphate, similar to our proposal. It
should be noted, however, that MraY is not able to break the
pyrophosphate bond in undecaprenyl pyrophosphate, most
likely because the pyrophosphate moiety cannot be accommo-
dated properly in the active site of the enzyme. Furthermore,
the pyrophosphate moiety present in UDP-MurNAc-penta-
peptide cannot be hydrolyzed by MraY in the absence of poly-
prenyl phosphate. MS analysis only showed exchange of 14N
and 15N isotopes between UMP and UDP-MurNAc-pentapep-
tide in the presence of C35-P, as was suggested by previous
studies using radiolabeled UMP (8). This result is also in line
with our finding that both substratesUDP-MurNAc-pentapep-
tide and C35-P need to bind before the products Lipid I and
UMP are liberated. However, it contradicts the formation of
phospho-MurNAc-pentapeptide from UDP-MurNAc-penta-
peptide, as has been postulated before (20).
The involvement of conformational changes in MraY trans-
locase activity has been suggested before based on inhibition
studies (1, 21, 22). The lysis protein E from bacteriophage
X174 strongly inhibits MraY from Gram-negative species.
Residues present inTM9were found to be implicated in protein
E binding (23). However,MraY fromGram-positive species are
not affected by protein E. Although a conformational change
similar to that proposed in, for example, MraY from E. coli
might still occur in the enzymes from Gram-positive species,
this could not be verified using protein E, because BsMraY does
not bind to protein E strongly if at all (23).
Reaction Mechanism—The translocase activity of MraY
requires clustering of the two substrates, UDP-MurNAc-pen-
tapeptide from solvent water and polyprenyl phosphate with its
hydrophobic tail embedded in the membrane environment.
Based on the crystal structure ofMraY fromA. aeolicus, Chung
et al. (6) proposed a reaction mechanism, where Asp-98 (Asp-
117 in Protein Data Bank entry 4J72) is involved in deprotona-
tion of the phosphatemoiety of polyprenyl phosphate, allowing
subsequent nucleophilic attack on bound UDP-MurNAc-pen-
tapeptide (e.g. as shown in Fig. 7). Alternatively, or in addition,
activation of the phosphatemoiety of polypropylene phosphate
may proceed involving His-289. When the reaction proceeds
according to themechanism shown, the oxyanion of polyprenyl
phosphate performs a nucleophilic attack on the phosphate
moiety of MurNAc-pentapeptide, leading to the formation of
Lipid I. Concomitantly, the phosphorus–oxygen bond between
UMP and the phosphate moiety of MurNAc pentapeptide is
broken. This SN2 type process is fully reversible, providing a
basis for the observed reaction, where incubations with UMP
and Lipid I give rise to UDP-MurNAc-pentapeptide and poly-
prenyl phosphate.
FIGURE 7. Concerted SN2 type mechanism of transferase reactions catalyzed by MraY; deprotonation of the phosphate moiety of polyprenyl phos-
phate allows subsequent nucleophilic attack on bound UDP-MurNAc-pentapeptide.
Catalytic Mechanism ofMraY
JULY 15, 2016•VOLUME 291•NUMBER 29 JOURNAL OF BIOLOGICAL CHEMISTRY 15063
 at IN
STY
TU
T BIO
CH
EM
II I BIO
FIZY
K
I on N
ovem
ber 4, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Alternative reaction mechanisms have been proposed where
the translocase reaction proceeds via a nucleophilic attack on
UDP-MurNAc-pentapeptide by an acidic residue in MraY (1)
(e.g. Asp-98). In this process, UMP will be liberated in a similar
fashion as shown in Fig. 7. A covalently bound phospho-Mur-
NAc-pentapeptide intermediate will then be formed, either
yielding Lipid I after reaction with polyprenyl phosphate or
reproducing UDP-MurNAc-pentapeptide in the presence of
high concentrations of UMP. It was found, however, that in the
absence of C35-P,MraY did not catalyze a nucleotide exchange
process between UDP-MurNAc-pentapeptide and UMP (Fig.
4). Our work strongly suggests that polyprenyl phosphate is
needed to activate MraY. This means that the alternative sce-
nario, in which the reaction proceeds via a nucleophilic attack
on UDP-MurNAc-pentapeptide by an acidic residue in the
enzyme, is less likely than a direct attack of polyprenyl phos-
phate on UDP-MurNAc-pentapeptide yielding Lipid I and
UMP, as illustrated in Fig. 7. When Lipid I is bound to the
enzyme, MraY may still reside in its activated form such that
activation of UMP is not required for the nucleophilic attack on
bound Lipid I, yielding UDP-MurNAc-pentapeptide and poly-
prenyl phosphate. It remains to be established in detail how the
essential histidine His-289 is catalytically involved in the trans-
locase activity of MraY. It is clear, however, that His-289 is not
simply involved in binding of either substrate. More likely, it is
needed to activate the phosphate moiety of the polyprenyl
phosphate. In this process, a (slight) conformational change in
MraY is essentially required for catalysis yielding Lipid I.
Whether or not His-289 is also catalytically required in the
reverse reaction between Lipid I and UMP remains to be estab-
lished as well.
Inhibition of Translocase Activity—The kinetics and docking
study presented here have given new insight into the mecha-
nism underlyingMraY catalysis. AlthoughMraY has long been
considered an ideal target for novel antimicrobial compounds,
the inhibitor development for this enzyme has so far not been
very successful. Most studies on inhibition of MraY to eventually
block peptidoglycan synthesis have been focused on competitive
inhibition by UDP-MurNAc-pentapeptide analogs, such as tuni-
camycin (24). Our current work provides structural insight into
how to possibly blockMraY activity by focusing on the polyprenyl
phosphate substrate; a promising approach would be to specifi-
cally alkylate or covalently block the essential histidine in the
enzyme (His-289 in BsMraY) using, for example, a competitive
inhibitor that mimics the polyprenyl substrate.
In addition, the noncompetitive inhibition of MraY from
Gram-negative species by protein E has been reported (11, 22,
23). Protein E inhibition of MraY is probably attributable to
locking the enzyme in an inactive configuration such that con-
formational change cannot take place. Although protein E is
found to be inactive againstGram-positiveMraY, the structural
homology of Gram-negative and Gram-positive MraY is such
that conformational changes needed to activate the enzyme are
very likely to be similar. If, indeed, the inhibition from E is due
to locking MraY in a form such that no accommodation of the
hydrophobic polyprenyl phosphate could occur, screening for
similar inhibitors that will also bind to Gram-positive species
will widen the scope for such an inhibition mechanism.
Experimental Procedures
Materials—Unless stated otherwise, all chemicals used were
purchased from Sigma-Aldrich. All DNA ladders, restriction
enzymes, and buffers were purchased from Thermo Fisher
Scientific. Oligonucleotides (primers) for DNA amplification
(PCRs) and sequencing were synthesized by Integrated DNA
Technologies (Leuven, Belgium). Sequencing services for all
DNAconstructs were provided byMacrogen (Amsterdam, The
Netherlands). pET28a vector was purchased from Merck Mil-
lipore (Amsterdam, The Netherlands). EDTA-free protease
inhibitor mixture tablets were obtained from Roche Diagnos-
tics (Risch-Rotkreuz, Switzerland). DDM was obtained from
Affymetrix (Santa Clara, CA). Precision Plus ProteinTM stan-
dards were purchased from Bio-Rad. Isopropyl--D-thiogalac-
topyranoside was purchased from Thermo Fisher Scientific.
	SlyD BL21 (DE3) E. coli strain was a kind gift from Prof. Ry
Young (TexasA&MUniversity, College Station, TX). LysCpro-
tease was purchased from Wako Pure Chemical Industries
(Osaka, Japan). Heptaprenol (C35-) and undecaprenol (C55-)
were isolated and then phosphorylated to C35-P and C55-P,
respectively, as described previously (25, 26).
RecombinantWild TypeMraY—ADNA fragment coding for
BsMraY protein was amplified from B. subtilis 168 by colony
PCR using the following primers: BamHI-BY, 5-ggatccatgctt-
gagcaagtcattcgtttac-3; BY-HindIII, 5-aagcttttataaccacacctcg-
3. The restriction sites are underlined. Standard protocols
were used for PCR amplification, digestion, ligation into
pET28a vector, recombinant plasmid transformation, and
propagation. The resulting expression plasmid was named
pET28a-BsY, which carries an N-terminal His6 tag, a thrombin
cleavage site, and a T7 tag. The sequence was confirmed by
sequencing analysis (Macrogen).
H289R-BsMraY—Site-directed mutagenesis was performed
on pET28aBsY to generate the single mutant H289R using
primers H289R-for (5-ctttaaaatgagtccgcttcgtcaccattatgagctt-
gtc-3) and H289R-rev (5-gacaagctcataatggtgacgaagcggact-
cattttaaag-3). Themismatch for arginine coding is underlined.
The protocol is based on one used previously (27) with con-
struct-specificmodifications. Briefly, PCRwas performedusing
Phusion polymerase with an annealing temperature of 72 °C for
50 s and plasmid elongation at 72 °C for 6min. DpnI (0.25l, 20
units/l) was added to the PCRmixture and incubated at 37 °C
for 1 h before transformation. Plasmid isolation was performed
subsequently using the Qiagen MiniPrep kit. The resulting
sequence was confirmed by sequencing analysis (Macrogen).
Protein Purification—For protein expression, we used an
E. coli strain that has a deletion in the slyD gene to prevent
contamination of the purifiedMraY with this protein. For each
preparation, pET28aBsY and mutant were freshly transformed
into competent	slyD BL21(DE3) E. coli cells and subsequently
inoculated into Luria broth (1% tryptone, 0.5% yeast extract,
and 1% NaCl) supplemented with kanamycin (50 g/ml) for
overnight growth at 37 °C. This preculture was diluted the next
day at a ratio of 1:100 into prewarmed (37 °C) Terrific broth
(1.2% tryptone, 2.4% yeast extract, 0.4% glycerol, 17 mM
KH2PO4, 72 mM K2HPO4) supplemented with kanamycin
(50g/ml). The growthwas continued at 37 °C up to anA600 nm
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of 0.5. Subsequently, isopropyl--D-thiogalactopyranoside
(final concentration  100 M) was added to induce protein
expression. The growthwas continued at 22 °C for 4 h. For each
batch of purifiedMraY, 5 liters of cells expressing BsMraY or its
mutant were harvested and disrupted by probe sonication. The
membrane was subsequently solubilized by the addition of 1%
DDM in buffer A (25mMTris-HCl (pH 7.6), 150mMNaCl, 10%
glycerol). The mixture was centrifuged at 206,000 
 g for 45
min. The supernatant was collected, and 1%DDMwas added to
the pellet for a second round of solubilization. The solubilized
membrane protein fractions were pooled and incubated with
Ni-NTA-agarose beads pre-equilibrated with buffer A sup-
plemented with 20 mM imidazole. Beads loaded with protein
were subsequently transferred to a gravity column for batch-
wise IMAC purification. Pure protein (purity higher than 90%)
was collected by eluting in two fractions with 250 and 500 mM
imidazole in buffer A, supplemented with 0.1% DDM. Produc-
tion of MraY was monitored by a TLC-based Lipid II synthesis
assay. The fractionsweremade into small aliquots and stored at
20 °C until further use.
UDP-MurNAc-Pentapeptide and [15N2]UMP Exchange
Assay—BsMraY (14 nM) in 0.1% DDM, either free from C35-P
or with C35-P at 100 M, was incubated with UDP-MurNAc-
pentapeptide (100 M) and uridine-[15N2]5-monophosphate
(1mM) for 16 h at room temperature inTris-HCl buffer (pH8.0)
supplementedwithMg2 (50mM). The detergent was removed
from the mixture using a C18 column before mass spectrome-
try measurements. Products were eluted in methanol/acetoni-
trile/water (2:2:1) and were analyzed with LC-MS to check
whether the 15N isotope was transferred from UMP to UDP-
MurNAc-pentapeptide. LC-MS analysis was performed on an
Exactivemass spectrometer (ThermoFisher Scientific) coupled
to a Dionex Ultimate 3000 autosampler and pump (Thermo
Fisher Scientific). TheMS operated in polarity-switchingmode
with spray voltages of 4.5 and 3.5 kV. Products were separated
using a Sequant ZIC-pHILIC column (2.1 
 150 mm, 5 m,
guard column 2.1 
 20 mm, 5 m; Merck). The flow rate was
set at 150 l/min, and products were separated using a linear
gradient of acetonitrile and eluent A (20 mM (NH4)2CO3, 0.1%
NH4OH in ULC/MS grade water (Biosolve)). Products were
identified and quantified using LCquan software (Thermo Sci-
entific) on the basis of exact mass within 5 ppm and further
validated by concordance with retention times of UMP and
UDP-MurNAc-pentapeptide standards.
TLC-based Lipid II Synthesis Assay—A TLC assay designed
to test Lipid II synthesis was used to monitor MraY activity.
In this assay, the MraY substrates C55-P (1 mM) and UDP-
MurNAc-pentapeptide (100 M), the MurG substrate UDP-
GlcNAc (0.5mM),MgCl2 (6.7mM), and pureMurG enzyme (20
nM) weremixedwith TritonX-100 (0.5%) in Tris-HCl (100mM,
pH 8.0) buffer with a total volume of 75 l. MraY-containing
membrane fraction, BsMraY, or its mutant H289R was added
last to initiate the synthesis. The reaction was quenched by the
addition of pyridine-HAc (pH 4.2) to the mixture after incuba-
tion at room temperature for 1 h. Immediately thereafter,
BuOH was added to the mixture, vortexed, and centrifuged
briefly to induce phase separation. The upper layer was isolated
andwashedwith 50l of water. After brief centrifugation, 10l
of the upper layer was dried in a desiccator. The residue was
taken up in CHCl3/MeOH (1:1, v/v) and spotted on a silica gel
plate. The plate was developed in CHCl3/MeOH/H2O/NH3
(88:48:10:1 by volume). The lipids were subsequently visualized
by iodide staining. C55-Lipid II was spotted as a reference.
Fluorescent Enhancement Assay and Kinetics Studies—MraY
activity is determined using a fluorescent enhancement assay
that was described earlier (28). Total volumes of 50 l consist-
ing of 25–400 M C35-P, 15–100 M UDP-MurNAc-penta-
peptide-DNS, 200mMTris-HCl (pH8.0), 0.5%TritonX-100, 50
mM MgCl2, 100 mM KCl were mixed in 96-well plates. BsMraY
(10 nM) was added with thorough mixing to initiate the reac-
tion. The increase of fluorescence at em 510 nm (excitation
wavelength ex 365 nm) was measured at 25 °C in a Spectra-
Max i3 microplate reader (Molecular Devices, Sunnyvale, CA).
The increase of fluorescence was due to Lipid I formation as a
result of the transfer of the dansyl label to a more hydrophobic
environment (i.e. from the water-soluble UDP-MurNAc-pen-
tapeptide to Lipid I embedded in amicelle). On the assumption
that equilibrium had been reached under these conditions and
using the known equilibrium constant (29) of 0.25 for the translo-
cation reaction, the fluorescence signal (in relative fluorescent
units) was converted into concentration of DNS-Lipid I
(702,239.3  0.3% relative fluorescent units/M). Rate equations
werederived for initial product formation ina randombi-bimech-
anism(Fig. 1A) and foraping-pongmechanism(Fig. 1B). Equation
1 for the random bi-bi mechanism turnover is as follows,
k 
kcat
1
Km
C35P
[C35-P]

Km
UMpp
[UMpp-DNS]

Ks
C35P
[C35-P]

Km
UMpp
[UMpp-DNS]
(Eq. 1)
where KmUMpp gives the affinity for UDP-MurNAc-penta-
peptide-DNS when a ternary complex is formed; KmC35-P
gives the affinity for C35-P when a ternary complex is
formed; and KsC35-P gives the affinity for C35-P when a
binary complex is formed. The dependent constantKsUMpp (i.e.
the affinity for UDP-MurNAc-pentapeptide-DNS when a
binary complex is formed) is obtained fromKsUMppKsC35-P

KmUMpp/KmC35-P.
Equation 2 shows ping-pong mechanism turnover. At t 0,
[UMpp-DNS]  0 and [Lipid I]  0. Therefore, the steps rep-
resented by the dotted arrows in Fig. 1B are ignored.
k 
kcat
1
Km
UMpp
[UMpp-DNS]

Km
C35-P
[C35-P]
(Eq. 2)
where kcat  k1 
 k2/(k1  k2); KmUMpp  KsUMpp 
 k2/(k1 
k2); and Km#C35-P KmC35-P
 k1/(k1 k2).
Experimentaldatawere fitted toEquation1or2usingnonlinear
regression (software JMP from SAS Inc. or GraphPad Prism).
Modeling of B. subtilis MraY—A structural model of BsMraY
was built on the basis of the crystal structure data (Protein Data
Bank code 4J72) of A. aeolicus MraY (AaMraY). The pairwise
query-template alignment was obtained after an HHpred (30)
search using the pdb70 database. In order to generate a global
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sequence alignment, we enabled the “Realign with MAC algo-
rithm” option and set the “MAC realignment threshold” to 0.0.
The alignment was then used in MODELLER 9v12 (31) to gen-
erate 100 models, which were scored and ranked using the
DOPE statistical potential (32). The lowest energy model pro-
vided the initial structure for the flexibility analysis with CON-
COORD (33) and was also included in the docking simulations.
Modeling ofHeptaprenyl Phosphate—The three-dimensional
structure of C35-P was obtained using ChemBioDraw version
13.0 (generation of MOL file), OpenBabel (34) (conversion to
Protein Data Bank), and Avogadro (35) (energy minimization
with the GAFF force field). The resulting energy-minimized
structure was then used in Antechamber/Acpype (36) with
default options to generate parameters and topology files for
HADDOCK (13). Given the natural flexibility of the C35-P mol-
ecule, we used HADDOCK (single-molecule refinement) to gen-
erateanensembleof initial conformations fordocking.During this
process, the C35-P molecule was defined as fully flexible, and the
explicit solvent refinement was carried out in DMSO, a lipid
mimic. Due to the high temperature simulated annealing proce-
dure and the parameter set we used, some of the resultingmodels
were in conformations that, given our understanding of the (bio)
chemistry of C35-P, we consider to be unrealistic. Hence, we
manually selected five of the refined conformers based on their
curvature, biasing toward mostly linear conformations, and
overall stereochemistry for use in the docking simulations,
instead of on the intramolecular energies alone.
Docking of Heptaprenyl Phosphate and B. subtilis MraY—
The interaction between BsMraY and C35-P wasmodeled with
HADDOCK (13) version 2.2 (37), using CNS (Crystallography
and NMR System) version 1.3 (38) for structure calculations.
Non-bonded interactionswere calculated using theOPLS force
field (39) using an 8.5 Å cut-off. The electrostatic interactions
weremodeled using aCoulombpotential including a shift func-
tion, whereas van der Waals interactions followed a Lennard-
Jones potential using a switching function between 6.5 and 8.5
Å. The force field parameters for themagnesium ionweremod-
ified tomatch those defined byAllne´r et al. (40), which describe
the interaction of the divalent cation with phosphate ionsmore
accurately. The partial charge of the ionwas also reduced to1
because docking with the full charge (2) posed several chal-
lenges, in particular with the negatively charged phosphate ion
of the substrate. The ion was also restrained to a coordinating
residue on MraY (Asp-231) using unambiguous distance
restraints to avoid drifting during the high temperature refine-
ment stages. TheHADDOCK score, a weighted sum of electro-
static, van der Waals, and restraint energy terms, was used to
rank the models. The default desolvation energy term, derived
for aqueous solution, was neglected because this system is
embedded in a membrane. To force the molecules to obey the
topology of the membrane, in the absence of an explicit bilayer
model, we implemented a novel energy term in CNS, which we
call “z-restraints” (not yet available in the standard 2.2 version
of HADDOCK). These allow us to keep specific sections of a
molecule in a particular subspace of the z (vertical) dimension
(e.g. transmembrane helices and the hydrophobic tail of C35-P
in the range of the thickness of the bilayer) and thus avoid
meaningless orientations. The following BsMraY residues were
restrained to a20 Å/20 Å z boundary: 5–39, 72–90, 96–118,
130–146, 175–198, 202–228, 238–257, 266–305, and 336–
355. These selections comprise -helical segments and were
based on the data shown by the OPM database for the AaMraY
structure and on the calculations on the BsMraY model using
the PPM2.0 server (15). All of C35-P was required to remain
inside the defined z boundaries.
We first ran a docking simulation to sample possible binding
surfaces of C35-P on MraY. This simulation used center-of-
mass restraints together with a single unambiguous distance
restraint with an upper limit of 7.5 Å between the terminal
phosphor atom of C35-P and the imidazole nitrogen atoms of
His-289 of BsMraY, in order to enforce the appropriate direc-
tionality of the C35-Pmolecule. The resultingmodels indicated
a patch of hydrophobic residues in BsMraY TM5 (residues
174–199), which is close to reported catalytically important
residues (Asn-168, Asn-171) but not a UDP-MurNAc-penta-
peptide binding site (8), as a putative binding surface of C35-P.
TheseTM5 residueswere subsequently used as passive residues
in a second round of docking simulations. For both simulations,
we generated 10,000 models during the rigid body energy min-
imization stage, and the 400 best scoring models were selected
for further refinement, which included semiflexible simulated
annealing and explicit solvent (DMSO) molecular dynamics.
The z-restraints were only active during the rigid body energy
minimization stage. The final refined models were clustered
using the fraction of common contacts algorithm (41) with a
cut-off of 0.75, and each cluster was ranked by the average
HADDOCK score of its four best members.
Flexibility Analysis of MraY—The conformational flexibility
of monomeric BsMraY was probed using CONCOORD (ver-
sion 2.1.2; available through the SBGRID consortium (42)) with
theOPLS-AA (43) van derWaals parameters and default bond/
angle parameters. As an input structure, we took the best-ranked
modelproducedbyMODELLER, judgedby itsDOPEscore.Given
the shortcomings of the homologymodel, namely the large inser-
tionscomparedwith theAaMraYstructure,we fixedsomepartsof
the model (residues 43–72 and 143–174) that would otherwise
dominate the analysis.All otherCONCOORDsettingswere left as
default. The GROMACS (44) tool “trjconv” was used to extract
representatives of the flexibility analysis.
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